Engflag

Delsym

Quick links to important sections

Delsym

Delsym_FR

Method of action: Antitussive, Cough And Cold Preparations

Treatment option: Cough

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Delsym

Quick Facts

Property Description
Active ingredient Dextromethorphan Polistirex
Form Oral Suspension / Liquid-Filled Capsule
Pharmacological class Non-opioid Antitussive (Cough Suppressant)
Common use Temporary relief of cough reflex
Origin Synthetic derivative (Morphinan class)

Delsym: Identity and Pharmacological Classification

Delsym is a well-recognized over-the-counter (OTC) medication, primarily known for its specialized active component, Dextromethorphan. This substance is formally classified as a non-opioid antitussive, belonging to the medical category of cough suppressants. Dextromethorphan is used as an OTC antitussive for controlling the cough reflex. Dextromethorphan is a synthetic compound, recognized chemically as a codeine analogue derived from the morphinan class. Its primary action is to provide temporary relief by controlling the reflex responsible for non-productive coughing caused by minor irritation in the throat and bronchial airways.

Composition and the Extended-Release Formulation

The defining feature of this medicine, differentiating it from generic cough liquids, is the use of Dextromethorphan Polistirex. This compound is a unique salt complex where the active Dextromethorphan is chemically bound to an ion-exchange resin to regulate its release. This Polistirex structure is formulated for sustained delivery. This mechanism ensures a significantly prolonged duration of action compared to standard immediate-release hydrobromide formulas. The resulting oral suspension is the primary dosage form designed for prolonged cough control, often positioned for extended relief due to its sustained effect.

General Purpose: Suppressing the Cough Reflex

The general purpose of this medicine is to elevate the cough threshold, thereby suppressing the frequency and intensity of the cough reflex. Dextromethorphan achieves this by acting centrally to interrupt the signals that typically trigger coughing. This targeted action provides effective relief, for example, when a patient experiences a persistent, dry cough disrupting routine activities or sleep. Serving exclusively as a cough controller, it operates without providing the pain relief or high sedative effects characteristic of the opioid group.

What side effects are possible with Delsym?

Possible Side Effects and Safety Information

The safety profile for Delsym (dextromethorphan polistirex) outlines potential adverse reactions and necessary restrictions for use, as documented in regulatory information.

Adverse Reactions (Commonly Reported)

Reported adverse effects are often categorized by frequency and the body system affected. Common, expected side effects that may occur include:

System-Organ Class Common Adverse Reactions
Nervous System Dizziness, Drowsiness, Excitation
Gastrointestinal Nausea, Vomiting, Constipation, Abdominal Discomfort

Less common reactions can include confusion, nervousness, and skin rash. Patients should note that the risk of certain neurological effects increases with higher than recommended doses (misuse or overdose).

Serious Adverse Reactions and Key Restrictions

Serious Reactions

Serious adverse reactions are rare but require immediate attention. These include the risk of Severe Allergic Reactions (such as swelling of the face, tongue, or throat, or trouble breathing) and Serotonin Syndrome, a potentially life-threatening event that can occur when dextromethorphan is combined with certain other medications, particularly MAO inhibitors.

Safety Restrictions and Contraindications

  • MAO Inhibitors: Delsym must not be used if a patient is currently taking a monoamine oxidase inhibitor (MAOI) or for 14 days after stopping an MAOI, due to the risk of Serotonin Syndrome.
  • Pediatric Use: The product is not for use in children under 4 years of age.
  • Chronic Conditions: Consult a healthcare provider before use if there is a chronic cough (e.g., from smoking, asthma, or emphysema) or a cough that occurs with excessive phlegm.
  • Duration: Use should be limited to no more than 7 days unless directed by a doctor.

Overdose and Emergency Response

The official regulatory documentation for Delsym (Dextromethorphan Polistirex) overdose specifies a range of clinical manifestations primarily affecting the central nervous system (CNS). Documented signs and symptoms include altered mental status, agitation, somnolence, confusion, unsteadiness (ataxia), tremor, and involuntary eye movements (nystagmus). Severe CNS manifestations listed are seizures, stupor, and coma. The cardiovascular system may present with rapid heartbeat (tachycardia) and either elevated or lowered blood pressure.

Overdose carries a documented risk of serious, potentially life-threatening outcomes, including severe respiratory depression, apnea (especially noted in young children), and the development of Serotonin Syndrome. Serotonin Syndrome is a particular risk when Dextromethorphan is co-ingested with other serotonergic agents.

Regulators mandate that immediate medical attention must be sought in all cases of suspected overdose. Explicit guidance requires contacting a Poison Control Center or emergency services right away, even if the individual appears to be asymptomatic. Management is defined as symptomatic and supportive care. Specific official procedures are documented, noting that interventions like gastric lavage are not recommended, and Naloxone can be considered for reversing specific central nervous system or respiratory depression effects.

Therapeutic Uses of Delsym

Delsym (Dextromethorphan Polistirex) is commonly used for managing symptoms related to the urge to cough. The medication is relevant in conditions characterized by episodic or fluctuating cough patterns and applied when symptoms create noticeable interference with daily stability.

Symptom and Condition Management

This medication is applied in situations involving certain distressing symptoms, specifically the dry cough reflex, which generally results from minor irritation of the throat and bronchial airways. It is commonly used in conditions associated with acute episodes of cough, such as those related to the common cold and the flu. This supportive relief helps address symptom clusters that interfere with daily comfort. The formulation is primarily used for managing indications including persistent non-productive cough, cough due to minor irritation, and cough associated with upper respiratory symptoms.

Therapeutic Benefit and Comfort

This formulation is commonly used for prolonged cough suppression, assisting with maintaining comfort when symptoms interfere with routine activities. It is relevant when short-term symptomatic assistance is needed, often applied during phases of increased distress or discomfort at night. This support contributes to easing discomfort during periods of heightened symptoms, and may assist with promoting restful sleep.

Quick Fact: Relief for Persistent Cough
Primary Use: Temporary suppression of the non-productive (dry) cough reflex.
Key Benefit: Supports the patient by easing the overall symptom load and distress.
Use Context: Relevant when coughing creates noticeable interference with sleep or routine activities.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Delsym?

Eligibility for using Delsym (Dextromethorphan Polistirex) is strictly defined by regulatory guidelines, primarily covering age, concurrent medication use, and pre-existing health conditions.

Approved and Restricted Populations

Population Group Eligibility Status (Regulatory Labeling)
Adults and Adolescents Approved for use (12 years and older).
Children 4 to under 12 Approved for use.
Children under 4 years Contraindicated (Must not use).
MAOI Users Contraindicated (Must not use, or within 14 days of stopping the drug).
Pregnant/Breastfeeding Conditional use; must consult a health professional before use.

Conditions Requiring Consultation

Regulatory documents specify that patients with certain pre-existing conditions must consult a doctor before using the medication. This includes individuals who have a chronic cough that persists or is accompanied by excessive phlegm (mucus). Similarly, those with a cough caused by chronic respiratory diseases like asthma or emphysema are subject to this conditional use restriction.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Delsym (Dextromethorphan Polistirex) is defined by pharmacokinetic and pharmacodynamic constraints documented in government regulatory sources.

Interaction scope Official Regulatory Documentation Statement
Medicinal product categories with documented interactions: Monoamine Oxidase Inhibitors (MAOIs), Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Potent CYP2D6 Inhibitors, Central Nervous System (CNS) Depressants.
Specific interacting medicines (if explicitly listed): Quinidine, Fluoxetine, Paroxetine, Methylene Blue, Alcohol (Ethanol), St. John’s Wort.
Mechanistic basis of interactions (only if stated in label): Pharmacokinetic interaction via CYP2D6 inhibition (resulting in reduced clearance); Pharmacodynamic interaction (resulting in additive serotonergic effects and additive CNS depression).
Timing-based interaction rules (if applicable): Do not use if currently taking an MAOI, or for 14 days after stopping an MAOI drug.
Population-specific interaction notes (if applicable): Individuals classified as CYP2D6 Poor Metabolizers are at increased risk for the drug’s toxic effects due to significantly higher plasma levels of the parent compound.
Interaction-related restrictions: Contraindicated combination with MAOIs; concomitant use with alcohol should be avoided; caution is required with co-administration of potent CYP2D6 inhibitors.

Official interaction statements:

  • Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly prohibited and requires a minimum of 14 days separation after discontinuing the MAOI.
  • Concomitant use with potent CYP2D6 inhibitors (e.g., Fluoxetine, Quinidine) is officially documented to increase the plasma concentration ( Cmax/ AUC) of the drug due to inhibited metabolic clearance.
  • Co-administration with other serotonergic agents (e.g., SSRIs, SNRIs) may result in additive effects, increasing the documented risk of Serotonin Syndrome.
  • Alcohol and other CNS depressants are noted for their potential to cause additive CNS depression, which can lead to enhanced drowsiness.

Connection to the overall interaction profile (2–4 sentences):

Regulatory documents establish the drug’s interaction structure primarily through the mandatory contraindication and a strict 14-day timing rule with MAOIs, alongside the pharmacokinetic risk of increased drug exposure stemming from CYP2D6 inhibition. Furthermore, the profile incorporates pharmacodynamic constraints with serotonergic agents and alcohol due to the documented potential for additive systemic effects, specifically Serotonin Syndrome and enhanced CNS depression.

Mechanism of Action

Central Mechanism for Reflex Dampening

The active ingredient, Dextromethorphan (DXM), induces a physiological response exclusively in the Central Nervous System (CNS) by acting directly on the medullary cough center in the brainstem. Its primary actions involve activating the high-affinity Sigma-1 (sigma1) receptor and blocking the excitatory NMDA receptor. This dual mechanism reduces the overall electrical excitability of the neurons responsible for generating the reflex impulse, leading to a physiological increase in the neural activation level required for reflex initiation.

Sustained Mechanistic Action via Polistirex

The unique Polistirex formulation is a specialized delivery mechanism that dictates the duration of sustained target engagement. The DXM molecule is chemically bound to an ion-exchange resin, which requires a slow, continuous dissociation process in the gastrointestinal tract. This regulated release maintains a stable concentration of DXM for up to 12 hours, ensuring the mechanism of central reflex dampening remains operational over a prolonged period.

Dosage and Administration Information

Official Administration Protocol for Delsym (Dextromethorphan Polistirex)

Usage of Delsym Extended-Release Oral Suspension is defined by its 12-hour dosing frequency and specific administration requirements. The medicine is administered via the oral route for short-term use.

To ensure proper dosing, the bottle must be shaken well before use to uniformly disperse the extended-release particles within the liquid. The dose must be measured only with the dosing cup provided with the product, a measure intended to prevent volume inaccuracies.

Labeled Dosing Regimens

The dosage schedule is determined by age, with the extended-release formulation requiring administration every 12 hours. The maximum limits must be strictly observed:

Age Group Single Dose Maximum Dose in 24 Hours
Adults and Children 12 Years and older 10 mL (60 mg DXM equiv.) 20 mL (120 mg DXM equiv.)
Children 6 to <12 Years 5 mL (30 mg DXM equiv.) 10 mL (60 mg DXM equiv.)
Children 4 to <6 Years 2.5 mL (15 mg DXM equiv.) 5 mL (30 mg DXM equiv.)
Children Under 4 Years Do not use Do not use

The drug is intended for temporary administration; instructions mandate discontinuation if the need for use persists for more than seven days.

Recent Clinical Evidence

Delsym: Recent Clinical Evidence

The active ingredient in Delsym is dextromethorphan polistirex, an extended-release formulation of the antitussive agent dextromethorphan. Research evidence for this formulation focuses on its performance in controlled settings, primarily for the temporary relief of cough.

Outcomes in Cough Suppression

Clinical studies, including randomized, placebo-controlled trials, have been conducted to evaluate the effects of dextromethorphan on acute cough associated with the common cold or other upper respiratory infections. Key findings reported in the research include:

  • Duration of Effect: The polistirex formulation is designed to release dextromethorphan over an extended period, which has been associated in studies with a longer duration of antitussive activity compared to immediate-release formulations.
  • Symptom Changes: In one pediatric study, the active agent was associated with a statistically significant reduction in cough frequency during the daytime in children aged 6 to 11 compared to the inactive control (placebo). However, a difference was not consistently observed in nighttime cough rates or impact on sleep measures.

Safety and Monitoring

Clinical safety monitoring has identified typical adverse events associated with dextromethorphan. These events are generally mild and commonly include dizziness, drowsiness, and gastrointestinal discomfort (such as nausea or vomiting).

Adverse Event Category Frequency in Clinical Trials
Central Nervous System Dizziness, Drowsiness, Fatigue
Gastrointestinal Nausea, Vomiting

It is important to note that the extended-release formulation's primary advantage, a longer dosing interval, necessitates caution regarding potential drug interactions, as plasma concentration levels are maintained over a longer period. The ingredient's metabolism is dependent on the CYP2D6 enzyme, a factor monitored in clinical development and relevant for individuals taking other medications that affect this enzyme.

Frequently Asked Questions (FAQ)

Common questions about Delsym (FAQ)

Q: How does Delsym (Dextromethorphan Polistirex) support cough relief?

A: Dextromethorphan, the active ingredient in Delsym, is understood to act on the cough center in the brain, potentially raising the threshold for a cough reflex. This action may lead to a temporary reduction in the frequency and intensity of coughing.

Q: Is there research on the duration of Delsym's effect?

A: Delsym utilizes a polistirex delivery system, which is intended to release the medication slowly. Clinical observations suggest that this formulation may provide a prolonged effect compared to immediate-release formulations of dextromethorphan.

Q: For what types of cough is Delsym generally used?

A: Delsym is typically used to temporarily quiet a cough caused by minor throat and bronchial irritation, which may occur with the common cold or inhaled irritants. It is not generally intended for persistent or chronic coughs, such as those caused by smoking, asthma, or emphysema.

Q: Can Delsym be taken with other cold medications?

A: It is essential to review the active ingredients of all medications being considered. Combining medications that both contain dextromethorphan or other similar cough suppressants is not advisable, as this can lead to an excessive intake of the ingredient. Consulting a healthcare professional or pharmacist is recommended before combining over-the-counter products.

Q: What is the main difference between Delsym and other dextromethorphan products?

A: The key distinction is the formulation. Delsym contains dextromethorphan polistirex, a extended-release form, while many other products contain dextromethorphan hydrobromide, an immediate-release form. The polistirex formulation is designed for a longer time-action profile.

How should Delsym be stored and disposed of?

The official regulatory labeling for Delsym (dextromethorphan polistirex extended-release suspension) defines specific requirements for product storage, handling, and disposal.

Storage Requirements

Classification Required Conditions
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep away from excess heat and moisture; do not freeze.
Container Keep in the original container and ensure the bottle is tightly closed.
Handling The suspension must be shaken well before use.

Safety and Disposal

The medicine must be stored out of the sight and reach of children. The regulatory documents mandate that outdated or unused medication must be properly discarded. Users should consult a pharmacist or local waste disposal company for instructions regarding proper disposal, and should not flush the medication down the toilet unless explicitly advised to do so.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagCanada

flagUSA

Equivalent of Delsym found in:

A-Z Index: